lncRNA expression is altered in cancer. Aberrant regulation promotes tumor formation, progression and metastasis. lncRNAs can use as tumor markers for PCa and may be attractive novel therapeutic targets for the diagnosis and treatment of PCa.
Prostate cancer plays an important role in widely understood aspects of men's health, and is becoming a growing problem in terms of public life. Prostate cancer is one of the most common neoplasms among men. Male patients can live with prostate cancer for a long time so it is important to offer appropriate males adequate diagnostic tools and treatments. Prostate cancer and PSA potentially represent a “pair” of a disease and an appropriate indicator to be used in mass screening, but regardless of that there is still active debate about it. Extensive use of PSA screening has modified epidemiology of the diseases. Randomized controlled studies provided sufficient results regarding a reduction in mortality through PSA mass screening, while all agreed on risks of overdiagnosis and overtreatment. New and accurate screening tools are necessary, along with adequate counseling and risk stratification.
INTRODUCTION AND OBJECTIVES:The VA Cooperative Studies Group Study #553 was designed to prospectively evaluate the efficacy of early adjuvant chemotherapy added to the standard of care (SOC) for patients with prostate cancer who are potentially cured by radical prostatectomy but who are at high risk for relapse based on clinical and pathologic parameters.METHODS: Patients at high risk for relapse after prostatectomy were randomized in 1:1 ratio to the SOC group of observation or to the chemotherapy group with docetaxel and prednisone administered every 3 weeks for 18 weeks. Randomization was stratified for PSA, Gleason score, tumor stage and the presence of positive margins, within each site. The primary endpoint was progression-free survival. Secondary endpoints included overall, prostate cancer-specific, and metastasis-free survival and time to initiation of androgen deprivation. Time to event data were compared using a log-rank test in the ITT analysis. Proportional hazards regression were used to calculate estimates of hazard ratio, adjusting for stratifying variables and incorporating site via a gamma frailty.RESULTS: A total of 297 patients randomized between July 2006 and October 2011 were included in the analysis (157 randomized to SOC and 140 to chemotherapy). The median follow-up was 62.4 months (range 0.2 to 104.3 months). For the primary endpoint, the two groups did not statistically differ in progression-free survival (median time to progression 55.5 months in chemotherapy group, 45.6 months in SOC group; logrank test p¼0.26; adjusted hazard ratio (HR) 0.82; 95% confidence interval (CI) 0.60-1.14). Subgroup analyses showed benefit in progression-free survival for patients with tumor stage T3b (HR 0.58, 95% CI 0.34-0.98, logrank test p¼0.041) and for African Americans (HR 0.54, 95% CI 0.29-1.01, p¼0.054). The secondary endpoint analyses are hampered by low event rates for all secondary endpoints. The most common adverse events Grade 3 related or possibly related to chemotherapy included neutropenia in 40%, hyperglycemia in 18%, and fatigue in 5%, with febrile neutropenia in 1.4%.CONCLUSIONS: Adjuvant chemotherapy in high-risk prostate cancer using docetaxel and prednisone was well tolerated and did not lead to statistically significant improvement in progression-free survival for the ITT population as a whole. Subgroup analyses suggest potential benefit for patients with higher risk pathology (pT3b) and African-American ancestry, supporting ongoing and planned trials of systemic chemotherapy for hormone-sensitive prostate cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.